Meeting
2019 ASCO Annual Meeting
Clinical, pathological and genetic predictors of patient-derived xenograft (PDX) engraftment in EGFR-mutated lung adenocarcinoma (LUAD).
Authors
Sebastiao N. Martins-Filho
University Health Network, University of Toronto, Toronto, ON, Canada
Sebastiao N. Martins-Filho , Jessica Weiss , Nhu-An Pham , Michael Cabanero , Aline Fusco Fares , Erin L. Stewart , Devalben Patel , Judy McConnell , Penelope Ann Bradbury , Adrian G. Sacher , Natasha B. Leighl , Alexandria Grindlay , Frances Allison , Ming LI , Kazuhiro Yasufuku , Frances A. Shepherd , Nadeem Moghal , Ming Sound Tsao , Geoffrey Liu
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics and Tumor Biology (Nonimmuno)
Track
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Sub Track
Other Developmental Therapeutics
Citation
J Clin Oncol 37, 2019 (suppl; abstr 3110)
DOI
10.1200/JCO.2019.37.15_suppl.3110
Abstract #
3110
Poster Bd #
102
Abstract Disclosures
Similar Posters
Poster
2019 ASCO Annual Meeting
Validation of broad panel clinical sequencing-based genomic risk stratification in patients with advanced lung adenocarcinomas.
First Author: Sam Whipple
Poster
2018 ASCO Annual Meeting
EGFR reporting in stage IV adenocarcinoma of the lung: Demographic predictors of EGFR testing and survival.
First Author: Shagufta Shaheen
Poster
2018 ASCO Annual Meeting
Outcomes of EGFR-mutant lung adenocarcinomas (AC) that transform to small cell lung cancer (SCLC).
First Author: Nicolas Marcoux
Poster
2016 ASCO Annual Meeting
Nomograms to predict the presence of EGFR mutations and ALK rearrangements in non-small-cell lung carcinoma.
First Author: Wenfeng Fang